Physician profile
Terri Overbee
NPI 1467420034
$3,222.18
in general payments reported to CMS, 2019-2025
21 companies · $653 in 2025
The $653 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $535 · 2023: $699 · 2024: $793 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.08 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $378.76 | 2021-2024 | Airsupra |
| Gilead Sciences, INC. | $241.88 | 2023-2024 | Epclusa |
| Genzyme Corporation | $233.81 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $225.04 | 2022-2023 | Crysvita |
| Genentech USA, INC. | $152.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $139.29 | 2024 | |
| Evoke Pharma, INC. | $124.55 | 2022 | |
| Phathom Pharmaceuticals, INC. | $123.68 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.11 | 2023 | |
| Abbott Laboratories | $121.85 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $120.82 | 2024 | Cresemba |
| Mylan Specialty L.P. | $120.68 | 2023 | Yupelri |
| Novo Nordisk INC | $120.58 | 2025 | Wegovy |
| Insulet Corporation | $116.62 | 2025 | Omnipod |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $93.00 | 2025 | Valtoco |
| Sumitomo Pharma America, INC. | $89.32 | 2025 | Myfembree |
| Idorsia Pharmaceuticals US INC | $79.66 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $59.13 | 2025 | |
| Janssen Pharmaceuticals, INC | $52.57 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $39.68 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Overbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.